It is apparent that almost all of the major trials conducted in Africa concern infectious diseases. Lately, the incidence rates of non-communicable diseases e.g. diabetes, hypertension and many cancers are rising. Most of the therapies for these conditions are tried either in Europe or USA mainly on caucasian participants yet it is well known ethnic differences affect the pharmacokinetics and dynamics of these treatments. Shouldn't proactive efforts be instituted to make trials for investigational products for non-communicable diseases be as global as possible. What do you think?

Reply

  • tkwahli tkwahli Jan. 14, 2011

    Very timely and interesting. My personal view is that there is a dissproportionate investment in trial for infectious diseases, particularly HIV. Don't get me wrong. We of course need a HIV vaccine and good treatments however there are also children dying of poor nutrition and women in child birth. We need to work on these areas too to improve health for all

  • jessegitaka Jesse Gitaka Jan. 15, 2011

    Yes Tkwahli, health for all.

  • ndrresearch dr richard Jan. 9, 2013

    CLINICAL TRIAL DIABETES. We will provide the drug and clinic HbA1c & Urinalysis machines if you can deal with local ethics & regulatory.
    We are a small voluntary research group who seek to do further clinical trials in diabetes. In Phase 2 European clinical trials, diabetics had all oral medication removed and they remained non-diabetic for 4 months. We wish to repeat these trials. If you are interested please contact me at: ndrresearch@aol.com

    Attached files: Diabetes_EASD_HbA1c_with_legend.jpg
  • jessegitaka Jesse Gitaka Jan. 10, 2013

    Thanks Dr. Richard.
    Kindly check your inbox.

Please Sign in (or Register) to view further.